Finding the endless frontier: Lessons from the life sciences innovation system for technology policy

Capitalism and Society

Volumn 5, Issue 1, 2010, Pages

  Cockburn, Iain M ^a   Stern, Scott ^b  

^a BOSTON UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955336179     PISSN: None     EISSN: 19320213     Source Type: Journal    
DOI: 10.2202/1932-0213.1071     Document Type: Article

References (64)

1. Acemoglu, Daron and Linn, Joshua (2004), "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, 119(3), 1049-1090.
2. Aghion, Philippe, Paul A. David and Dominique Foray (2009a), "Science, Technology and Innovation for Economic Growth: Linking Policy Research and Practice in 'STIG Systems'" Research Policy, 38(4), 681-693.
3. Aghion, Philippe, Fiona E. Murray, Mathias Dewatripont, Julian Kolev and Scott Stern, (2009b), "Mice and Academics: Examining the Effect of Openness on Innovation," NBER Working Paper No. W14189.
4. Arora, Ashish, Andrea Fosfuri, Alfonso Gambardella (2001), Markets for Technology: Economics of Innovation and Corporate Strategy, MIT Press.
5. Burrill & Company (2008), Biotech 2008. http://www.burrillandco.com/ bio/biotech-book. Accessed August 3, 2007.
6. Carlsson, Arvid (1983), "The Role of Basic Biomedical Research in New Drug Development" in F. Gross (ed.), Decision-making in Drug Research, New York: Raven Press.
7. Cockburn, Iain M. (2004), "The Changing Structure of the Pharmaceutical Industry," Health Affairs, 23(1), 10-22.
8. - (2007), "Is the Pharmaceutical Industry in a Productivity Crisis?" Chapter in A. Jaffe, J. Lerner, and S. Stern (eds.), Innovation Policy and the Economy, Volume 7, MIT Press for the National Bureau of Economic Research, Cambridge MA.
9. - (2008), "Global Innovation in Pharmaceuticals" in David Mowery, Jeff Macher and Stephen Merrill (eds.), Globalization of Innovation: Emerging Trends in IT, Biopharma and Financial Services, National Academies Press, Washington DC.
10. Cockburn, Iain M. and Rebecca M. Henderson (1995), "Public-private interaction in pharmaceutical research," Proceedings of the National Academy of Sciences 92/93, 12 November 1996, 12725-12730.
11. - and - (1998), "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery," Journal of Industrial Economics, 46(2).
12. Cockburn, Iain M., Rebecca Henderson and Scott Stern (2000), "Untangling the origins of competitive advantage," Strategic Management Journal, 21, 1123-1145.
13. Cortright, Joseph and Heike Mayer (2002), Signs of Life: The Growth of Biotechnology Centers in the U.S., Brookings Institution Press.
14. Dasgupta, Partha and Paul A. David (1994), "Towards a new economics of Science," Research Policy.
15. Duggan, Mark G. and William N. Evans (2008), "Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments," Forum for Health Economics & Policy, 11(2) (Economics of the HIV Epidemic), Article 1. http://www.bepress.com/fhep/11/2/1
16. Ellison, Sara, Iain Cockburn, Zvi Griliches, and Jerry Hausman (1997), "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins", RAND Journal of Economics, 1997, 28(3), 426-446.
17. Feldman, Maryann (2003), "The Locational Dynamics of the US Biotech Industry: Knowledge Externalities and the Anchor Hypothesis," Industry and Innovation, 10(3), 311-328.
18. Finkelstein, Amy (2004), "Static and dynamic effects of health policy: Evidence from the vaccine industry," Quarterly Journal of Economics, 119(2), 527-564.
19. Freeman Richard and John Van Reenen (2009), "What if Congress Doubled R&D Spending on the Physical Sciences?" Center of Economic Performance Discussion Paper.
20. Gambardella, Alfonso (1995), Science and Innovation: The U.S. Pharmaceutical Industry during the 1980s, Cambridge University Press.
21. Gans, Joshua S., David H. Hsu, and Scott Stern. (2002) "When Does Start-Up Innovation Spur the Gale of Creative Destruction?" The RAND Journal of Economics, (33)4.
22. Gans, Joshua S., and Scott Stern (2003), "The Product Market and the Market for 'Ideas': Commercialization Strategies for Technology Entrepreneurs," Research Policy, 32(2), 333-350.
23. Garthwaite, Craig L. (2009), Empirical Essays in Health Economics, PhD Dissertation, University of Maryland.
24. Grabowski, Henry and John Vernon (1996), "Longer Patents for Increased Generic Competition: The Waxman-Hatch Act After One Decade," PharmacoEconomics, 10, 110-123.
25. Henderson, Rebecca and Iain M. Cockburn (1994), "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research", Strategic Management Journal, 15.
26. Hsu, David H. and Kwanghui Lim (2009), "The Antecedents and Innovation Consequences of Organizational Knowledge Brokering Capability," MBS Working Paper.
27. Jaffe, Adam B., and Josh Lerner (2004), Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It, Princeton, NJ: Princeton University Press.
28. Johnson I.S. (1983), "Human insulin from recombinant DNA technology," Science, 219(4585), February 11.
29. Jones, Benjamin F. (2008), "The Burden of Knowledge and the 'Death of the Renaissance Man': Is Innovation Getting Harder?" Review of Economic Studies, 76(1), 283-317.
30. Kenney, Martin (1986), Biotechnology: the University-Industrial Complex, New Haven, CT: Yale University Press.
31. Kyle, Margaret K. (2007), "Pharmaceutical price controls and entry strategies," Review of Economics and Statistics, 89, 602-618.
32. Lerner, Josh (1995), "Patenting in the Shadow of Competitors," Journal of Law and Economics, 38(2).
33. Lichtenberg, Frank R. (1995), "The Output Contributions of Computer Equipment and Personnel: A Firm-Level Analysis," Economics of Innovation and New Technology, 3.
34. - (1998). "Pharmaceutical Innovation, Mortality Reduction, and Economic Growth," NBER Working Paper No. 6569.
35. - (2001). "The Effect of New Drugs on Mortality from Rare Diseases and HIV," NBER Working Paper No. 8677.
36. - (2005). "The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001," International Journal of Health Care Finance and Economics, 5(1).
37. - (2008). "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," NBER Working Paper No. 14008.
38. Lichtenberg, Frank R. and Tomas J. Philipson (2002), "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US Pharmaceuticals Industry," Journal of Law and Economics, 45.
39. Lundvall, Bengt-Ake (1992), National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning, London: Pinter Publishers.
40. Maxwell, Robert A. and Shohreh B. Eckhardt (1990), Drug discovery: a casebook and analysis, The Humana Press, Inc., pp. 409.
41. McKelvey, Maureen D. (1996), "Discontinuities in Genetic Engineering for Pharmaceuticals? Firms Jumps and Lock-in in Systems of Innovation," Technology Analysis & Strategic Management, 8(2), 107-116.
42. Merton, Robert K. (1973), The Sociology of Science: Theoretical and Empirical Investigations, Chicago: University of Chicago Press.
43. Mowery, David (2004), Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act in the United States, Stanford, CA: Stanford Business Books.
44. Mowery, David C. and Richard R. Nelson (1999), Sources of industrial leadership: studies of seven industries, New York: Cambridge University Press.
45. Mowery, David C. and Nathan Rosenberg (1998), Paths of innovation: technological change in 20th century America, New York: Cambridge University Press.
46. Murray, Fiona (2010), "The Oncomouse that Roared: Hybrid Exchange Strategies as a Source of Productive Tension at The Boundary Of Overlapping Institutions," American Journal of Sociology, Forthcoming.
47. Murray, Fiona and Scott Stern (2007), "Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis," Journal of Economic Behavior and Organization, 63(4), 648-687.
48. Nelson, Richard R. (1993), National Innovation Systems A Comparative Analysis, New York: Oxford University Press.
49. Nelson, Richard R. and Nathan Rosenberg (1994), "American universities and technical advance in industry," Research Policy, 23(3), 323-348.
50. Nelson Richard R. and Gavin Wright (1992), "The Rise and Fall of American Technological Leadership: The Postwar Era in Historical Perspective," Journal of Economic Literature, 30(4), 1931-1964.
51. Powell, Walter W., Douglas R. White, Kenneth W. Koput, Jason Owen-Smith (2005), "Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences," American Journal of Sociology, 110, 1132-1205.
52. Rosenberg, Nathan (2008), "Some Critical Episodes in the Progress of Medical Innovation: An Anglo-American Perspective," SIEPR Discussion Paper No. 08-08
53. Scherer, F. M. (2001), "The Link between Gross Profitability and Pharmaceutical R&D Spending," Health Affairs, 20(5), 216-222.
54. Schwartzman, David (1976), Innovation in the Pharmaceutical Industry, Baltimore: Johns Hopkins University Press.
55. Stern, Scott (1995), "Incentives and Focus in University and Industrial Research: the Case of Synthetic Insulin," Chapter in Geligns, A. and Rosenberg, N. (eds.), The University-Industry Interface and Medical Innovation, Institute of Medicine: National Academy Press.
56. - (1996), Market Definition and the Returns to Innovation: Substitution Patterns in Pharmaceutical Markets, Unpublished MS.
57. - (2004), "Do Scientists Pay to Be Scientists?", Management Science, 50(6).
58. Stokes, Donald E. (1996), Pasteur's Quadrant, Washington DC: Brookings Institution Press.
59. Thomas, Lacy G. (1990), "Regulation and Firm Size: FDA Impacts on Innovation," The RAND Journal of Economics, 21(4).
60. Utterback, James (1994), Mastering the dynamics of innovation: How companies can seize opportunities in the face of technological change, Boston: Harvard Business School Press.
61. Walsh, John P., Ashish Arora, and Wesley M. Cohen (2003), Effects of Research Tool Patents and Licensing on Biomedical Innovation. Chapter in Cohen, W.M. and Merrill, S.A. (eds), Patents in the Knowledge-Based Economy, Washington DC: National Academies Press.
62. Wuchty, Stefan, Benjamin F. Jones, and Brian Uzzi (2007), "The Increasing Dominance of Teams in Production of Knowledge," Science, 18 May 2007, 316(5827), 1036-1039.
63. Xu, Jiaquan et al (2009), "Deaths: Preliminary Data for 2007," National Vital Statistics Reports, National Center for Health Statistics.
64. Zucker, Lynn, Michael R. Darby and Marilynn B. Brewer (1998), "Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises," The American Economic Review, 88(1), 290-306.